Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant
|ClinicalTrials.gov Identifier: NCT00099749|
Recruitment Status : Completed
First Posted : December 20, 2004
Last Update Posted : February 23, 2017
|Condition or disease||Intervention/treatment||Phase|
|Kidney Transplantation||Drug: FTY 720||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||255 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant|
|Study Start Date :||November 2003|
|Actual Primary Completion Date :||April 2006|
- Biopsy-proven acute rejection (BPAR), graft loss, death and study discontinuation, within 6 months post transplantation.
- Safety/tolerability based on adverse event reporting.
- BPAR, graft loss, death and study discontinuation, within 6 and 12 months post transplantation.
- Efficacy parameters between the 3 treatment groups within 6 and 12 months post-transplantation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00099749
|United States, Illinois|
|Loyola University Medical Center|
|Maywood, Illinois, United States, 60153|
|SIU School of Medicine|
|Springfield, Illinois, United States, 62781|
|United States, New Jersey|
|St. Barnabas Medical Center|
|Livingston, New Jersey, United States, 07039|
|United States, Pennsylvania|
|University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|
|United States, Rhode Island|
|Rhode Island Hospital|
|Providence, Rhode Island, United States, 02903|